Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06HZA
|
|||
| Former ID |
DNCL003580
|
|||
| Drug Name |
GSK2586184
|
|||
| Synonyms |
GSK-2586184
Click to Show/Hide
|
|||
| Indication | Systemic lupus erythematosus [ICD-11: 4A40.0; ICD-9: 710] | Phase 2 | [1] | |
| Arthritis [ICD-11: FA20] | Phase 1 | [2] | ||
| Company |
GlaxoSmithKline
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H23N5O2
|
|||
| Canonical SMILES |
CC1(CN(C1)C(=O)C2=CC=C(C=C2)C3=CC=CC4=NC(=NN43)NC(=O)C5CC5)C
|
|||
| InChI |
1S/C22H23N5O2/c1-22(2)12-26(13-22)20(29)16-10-6-14(7-11-16)17-4-3-5-18-23-21(25-27(17)18)24-19(28)15-8-9-15/h3-7,10-11,15H,8-9,12-13H2,1-2H3,(H,24,25,28)
|
|||
| InChIKey |
MPYACSQFXVMWNO-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1206163-45-2
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01777256) An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT01336244) GLPG0778: Multiple Ascending Oral Doses, Pharmacokinetic, Safety, and Pharmacodynamic Study. U.S. National Institutes of Health. | |||
| REF 3 | DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184. Lupus. 2015 May;24(6):648-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.